Literature DB >> 14552742

Clinical presentation and follow up of children with congenital toxoplasmosis in Brazil.

Marco A P Sáfadi1, Eitan N Berezin, Calil K Farhat, Eduardo S Carvalho.   

Abstract

We evaluated the clinical presentation and determined the ocular and neurologic sequelae in children with congenital toxoplasmosis in Brazil, taking into consideration the shortage of national publications on this disease. Follow-up evaluations were made of 43 children with congenital toxoplasmosis referred to Santa Casa de São Paulo, during a period of at least five years. Selection of the cases was based in clinical and laboratory criteria. A clear predominance of children with subclinical presentation of the disease at birth (88%) was found. Of the 43 children, 22 (51%) developed neurological manifestations. Using skull radiography, we detected neuroradiologic alterations in seven children (16%) and with tomography in 33 children (77%). Neurological sequelae were identified in 15 children (54%) in the group with cerebral calcifications and in 7 (47%) in the group without cerebral calcifications. We observed chorioretinitis in 95% of the cases. Reactivation of cicatricial lesions and the emergence of new ocular lesions were observed in five cases. The most frequent neurological manifestation was a delay in neuropsychomotor development. Most remarkable was the finding that cerebral calcifications were not associated with a higher incidence of neurological sequelae among the children. Chorioretinitis was the main ocular sequel of the infection, found in nearly all children; it can manifest years from birth, even in children submitted to specific therapy druing the first year of life, highlighting the importance of a follow-up of these children.

Entities:  

Mesh:

Year:  2003        PMID: 14552742     DOI: 10.1590/s1413-86702003000500007

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  7 in total

1.  Globe calcification in congenital toxoplasmosis.

Authors:  N R S Surendrababu; K A Kuruvilla; A K Jana; Rekha Cherian
Journal:  Indian J Pediatr       Date:  2006-06       Impact factor: 1.967

2.  Neonatal hepatitis with toxoplasmosis.

Authors:  Sweta Mohanty; Ira Shah; Sushmita Bhatnagar
Journal:  J Clin Neonatol       Date:  2012-04

3.  MHC Class I Chain-Related Gene A Polymorphisms and Linkage Disequilibrium with HLA-B and HLA-C Alleles in Ocular Toxoplasmosis.

Authors:  Christiane Maria Ayo; Ana Vitória da Silveira Camargo; Fábio Batista Frederico; Rubens Camargo Siqueira; Mariana Previato; Fernando Henrique Antunes Murata; Aparecida Perpétuo Silveira-Carvalho; Amanda Pires Barbosa; Cinara de Cássia Brandão de Mattos; Luiz Carlos de Mattos
Journal:  PLoS One       Date:  2015-12-16       Impact factor: 3.240

4.  The impact of socioeconomic factors on the efficiency of voluntary toxoplasmosis screening during pregnancy: a population-based study.

Authors:  A E Lange; J R Thyrian; S Wetzka; S Flessa; W Hoffmann; M Zygmunt; C Fusch; H N Lode; M Heckmann
Journal:  BMC Pregnancy Childbirth       Date:  2016-07-29       Impact factor: 3.007

Review 5.  Basal ganglia calcifications (Fahr's syndrome): related conditions and clinical features.

Authors:  Giulia Donzuso; Giovanni Mostile; Alessandra Nicoletti; Mario Zappia
Journal:  Neurol Sci       Date:  2019-07-02       Impact factor: 3.307

6.  Congenital toxoplasmosis and prenatal care state programs.

Authors:  Mariza M Avelino; Waldemar N Amaral; Isolina M X Rodrigues; Alan R Rassi; Maria B F Gomes; Tatiane L Costa; Ana M Castro
Journal:  BMC Infect Dis       Date:  2014-01-18       Impact factor: 3.090

7.  Congenital toxoplasmosis in a reference center of Paraná, Southern Brazil.

Authors:  Jaqueline Dario Capobiango; Regina Mitsuka Breganó; Italmar Teodorico Navarro; Claudio Pereira Rezende Neto; Antônio Marcelo Barbante Casella; Fabiana Maria Ruiz Lopes Mori; Sthefany Pagliari; Inácio Teruo Inoue; Edna Maria Vissoci Reiche
Journal:  Braz J Infect Dis       Date:  2014-03-22       Impact factor: 3.257

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.